Revision as of 04:20, 3 April 2023 by Entranced98(talk | contribs)(Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound")
Duligotuzumab (INN) is a bispecific humanized IgG1 monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFR and HER3.[1] It is in development by Roche. Clinical development for head and neck cancer and colorectal cancer have been discontinued, but phase I trials in combination with cobimetinib are evaluating safety for treatment of solid tumors.[2]